SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that
Professor Lucie Clapp will present a
poster at the American Heart Association (AHA) Scientific Sessions
2016 on Monday, November 14 at
10:45am CT. The scientific
sessions are taking place November 12-16,
2016 in New Orleans,
Louisiana at the Ernest N. Morial Convention Center.
The following poster will be presented:
APD811, a Novel and Highly Selective Non-prostanoid IP
Receptor Agonist in Smooth Muscle Cells From Patients With
Pulmonary Hypertension
Session Type: Abstract Poster Session
Session Number: VA.APS.P189
Poster Session: Novel Mechanisms of Pulmonary Vascular
Disease
Date: Monday, November 14, 2016,
10:45 am - 12:00 noon
Location: Ernest N. Morial Convention Center, Science and
Technology Hall-Clinical Science Section
About Arena Pharmaceuticals
We are a biopharmaceutical
company focused on developing novel, small molecule drugs across a
range of therapeutic areas. We have three primary proprietary
investigational clinical programs: etrasimod (APD334) in Phase 2
evaluation for ulcerative colitis, APD371 entering Phase 2
evaluation for the treatment of pain associated with Crohn's
disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH). Additionally, we have
collaborations with the following pharmaceutical companies: Eisai
Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd.
(Phase 2 candidate), and Boehringer Ingelheim International GmbH
(preclinical candidate).
Our US operations are located in San
Diego, California. Our primary clinical operations are
located in Zug, Switzerland, and
our commercial manufacturing for BELVIQ is located in Zofingen,
Switzerland.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming presentation; and Arena's focus,
primary programs and collaborations. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Contact: Arena Pharmaceuticals,
Inc.
Kevin R. Lind, Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Logo - http://photos.prnewswire.com/prnh/20161107/436843LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-poster-at-the-american-heart-association-aha-scientific-sessions-2016-300359513.html
SOURCE Arena Pharmaceuticals, Inc.